Tagrisso, which targets exon 19 deletions or exon 21 (L858R) mutations, received the approval following a priority review.

Biotech reported positive interim data from a mid-stage trial of a treatment for the rare muscle disorder Duchenne muscular ...

TAGRISSO is indicated for patients with exon 19 deletions or exon 21 (L858R) mutations, as detected by a FDA-approved test. The approval follows a Priority Review by the Food and Drug Administration ...

Wave Life Sciences reveals positive interim data from its Phase 2 FORWARD-53 study on WVE-N531 for Duchenne muscular ...

In the phase 2 FORWARD-53 study, the exon-skipping oligonucleotide WVE-N531 showed promising safety and efficacy in boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.

J.P. Morgan analyst Eric Joseph maintained a Buy rating on Wave Life Sciences (WVE – Research Report) today and set a price target of ...

Zipalertinib appeared safe and effective in the treatment of heavily pretreated patients with non-small cell lung cancer ...

On September 19, the FDA handed down its third amivantamab (Rybrevant; Johnson & Johnson) approval for 2024 in non–small cell lung cancer (NSCLC), giving the third-generation tyrosine kinase inhibitor ...

We interviewed Sangeeta Shukla, Ph. D., a Bioinformatics Scientist for the Children’s Hospital of Philadelphia. We asked her ...

Results showed treatment with osimertinib reduced the risk of disease progression or death by 84% compared with placebo.

Amivantamab plus chemo is now indicated in locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R ...

The FDA has approved Tagrisso (osimertinib)​ to treat patients with unresectable, stage III, EGFR-mutant NSCLC whose disease has not progressed during or after chemoradiotherapy.